By the Top Tier Newswire AI Desk · July 29, 2026 at 9:33 AM ET · reviewed against 7 wire stories
NEOGENOMICS INC (NEO) is drawing unusual attention today. Our newswire has captured 7 stories on NEO across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
NEO stock surged 16.04% to $15.55 in early trading on July 29, 2026, driven by a combination of strong Q2 2026 earnings results and revised guidance from the company. The stock opened with a 11.9% gap up from the previous close and reached a session high of $16.10 before settling near $15.53. The move followed a series of analyst upgrades and updated financial projections that signaled improved performance in clinical and next-generation sequencing (NGS) segments.
What Happened
On July 28, NeoGenomics filed a Form 8-K disclosing preliminary results for the second quarter of 2026. The company reported non-GAAP earnings per share of $0.05, exceeding estimates by $0.02, and revenue of $202 million, which beat estimates by $5.01 million. The firm also raised its full-year 2026 revenue guidance from $797 million to $803 million to $802 million to $806 million. The company attributed the strong performance to growth in clinical and NGS services, though it noted weaker performance in nonclinical pharma segments. Needham upgraded the stock with a higher price target of $19, citing the results. Benchmark also raised its price target to $16 and maintained a Buy rating.
What The Data Shows
The stock opened at $15.00, a $1.60 gap up from the prior close, and traded with a narrow range throughout the session. Volume of 0.3 million shares was below the 3-month average by 90%. The stock is currently trading near its 52-week high of $15.57 and has a market capitalization of $1.7 billion. Despite the recent revenue growth of 10.9% trailing twelve months, the company remains unprofitable with a net margin of -13.3% and an EPS TTM of -0.77. The stock’s beta of 1.74 suggests it is more volatile than the broader market.
What To Watch
The company’s updated guidance and analyst upgrades indicate continued focus on clinical and NGS growth. Investors should monitor the company’s progress in pharma services and any further guidance adjustments. No earnings date is provided, but coverage breadth remains strong with eight stories from four sources in the last 36 hours.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
NEO · Jul 29 session (5-min) · +15.67% vs prior close · updated 6:12 PM ETAI sentiment, last 36h · averaged over 7 stories · 64/100 bullish
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
18h agoMarketChameleonBULLISH 73Earnings
NeoGenomics Lifts Outlook as NGS Revenue Jumps 26% and Margins Improve
July 29, 2026
NeoGenomics posted an 11% year-over-year revenue gain in Q2 2026, powered by 26% growth in next-generation sequencing (NGS) services and disciplined cost management. The company’s raised full-year guidance highlights a focus on margin expansion, clinical test growth, and a strengthened balance sheet.
19h agoSeeking AlphaBULLISH 71Earnings
NeoGenomics stock jumps 15% after beat and raise
NeoGenomics (NEO) stock jumps 15% after Q2 earnings beat and higher 2025 revenue outlook.
NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical testing and continued expansion in next-generation sequencing. Total second-quarter revenue rose 11% ye
Frequently asked questions
Why is NEO stock moving today?
NEOGENOMICS INC (NEO) is drawing unusual attention today. Our newswire has captured 7 stories on NEO across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100). The most recent driver: "NeoGenomics Lifts Outlook as NGS Revenue Jumps 26% and Margins Improve
July 29, 2026" (MarketChameleon).
Is NEO a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of NEO coverage reads 64/100 over 7 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →